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Abstract
Prostate cancer (PCa) has been linked to fat intake, but the effects of both different dietary fat levels and types remain inconsistent and incom-
pletely characterised. The effects on PCa in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer model of an elevated fat
(20 % of energy as fat) diet containing 155 g of whole walnuts were compared to those of an elevated fat (20 % of energy as soyabean oil) diet
with matched macronutrients, tocopherols as well as a low-fat (8 % of energy as soyabean oil) diet. Mice, starting at 8 weeks of age, consumed
one of the three different diets ad libitum; and prostates, livers and blood were obtained after 9, 18 or 24 weeks of feeding. No differences were
observed in whole animal growth rates in either high-fat (HF) diet group, but prostate tumour weight and growth rate were reduced in the
walnut diet group. Walnut diet group prostate weight, plasma insulin-like growth factor 1, resistin and LDL were lower at 18 weeks, while
no statistically significant prostate weight differences by diet were seen at 9 or 24 weeks. Multiple metabolites in the livers differed by diet
at 9 and 18 weeks. The walnut diet’s beneficial effects probably represent the effects of whole walnuts’ multiple constituents and not via a
specific fatty acid or tocopherols. Moreover, as the two HF diets had dissimilar effects on prostate tumour growth rate and size, and yet
had the same total fat and tocopherol composition and content, this suggests that these are not strongly linked to PCa growth.
Key words: Prostate cancer: Transgenic adenocarcinoma of the mouse prostate model: Fat: Whole foods: Insulin-like growth
factor 1: Chemoprevention
Prostate cancer (PCa), a leading cause of male cancer
deaths(1), has been linked to fat intake(2), but the effects of
both dietary fat levels and differences in unsaturated fatty
acids on prostate as well as other cancers remain inconsistent
and poorly characterised. Studies have suggested that n-3 fatty
acids inhibit(3–5) or have no effect(6,7) on PCa, while n-6
fatty acids stimulate PCa development(8). Hori et al.(9), in a
very recent review, concluded that there was little evidence
to suggest that a high-fat (HF) diet is associated with increased
PCa risk, but still suggested that reduced dietary fat intake in
combination with a healthy diet and lifestyle may slow the
progression of PCa in certain patients. Although high in fat,
walnut fats are mainly polyunsaturated and the effects of con-
suming walnuts on PCa are unclear(10). In addition, Freedland
and co-workers have reported that mouse PCa xenograft
tumour growth is not associated with dietary fat content(11,12).
Moreover, Hardman & Ion(13) have shown that implanted
MDA-MB 231 human breast cancer growth in nude mice
was significantly less in the group consuming walnuts
(human equivalent of two servings a day) compared to a
control group fed maize oil and have just reported that
walnuts suppress mammary gland tumorigenesis in the
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† Present address: Department of Medicine, Division of Oncology, National Jewish Health, Denver, CO 80 206, USA.
Abbreviations: GUI, genitourinary intact; HF, high-fat diet; IGF-1, insulin-like growth factor 1; LF, low-fat diet; NE, neuroendocrine; PCa, prostate cancer;
TRAMP, transgenic adenocarcinoma of the mouse prostate; WW, whole walnut diet.
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C(3)1 TAg mouse but the effect could not be accounted for by
the n-3 content alone(13,14).
The present study evaluated the effects of whole walnuts
fed as part of a moderately HF diet on tumour growth in the
transgenic adenocarcinoma of the mouse prostate (TRAMP)
animal cancer model(15). The high-fat, non-walnut diet was
formulated using tocopherol-stripped soyabean oil to achieve
not only the same fat levels but supply substantially similar
fatty acid profiles as well. The experimental and control
diets’ a- and g-tocopherol levels were equalised. Importantly,
the present study’s experimental diet was formulated incor-
porating whole walnuts as a unit, i.e. as whole food. Walnuts
contain multiple ingredients that have been reported to reduce
cancer risk or growth rate(16–20). The use of whole walnuts in
the study diets was adopted in response to the contrasting
results found when specific compounds were tested alone
compared with as part of a food. A recent example is the
report of Hsu et al.(21) who found that an isoflavone-rich
soya extract induced apoptosis in human PCa cells without
inducing apoptosis in benign prostate hyperplasia cells in con-
trast to specific soya isoflavones at the same levels as the
extract induced apoptosis in both cell types(21). An increasing
number of such studies suggest that foods exert effects
beyond those of any one constituent(22). The present work
represents the first study examining the effects of whole
walnut-containing diet on PCa in an animal model.
Materials and methods
Animals
C57/BL6 TRAMP £ C57BL/6 male PB-Tag Line 8247 transgene
mice were purchased from Jackson Laboratories. Mice (6–7
weeks old) were fed a laboratory rodent diet (no. 5001,
Ralston Purina) for 1 week, then weighed and randomised by
weight into three experimental dietary groups (ten to
fifteen mice per group) for each of three feeding durations (9, 18
and 24 weeks of ad libitum feeding). The mice were housed
four to a wire-bottomed cage with activity enhancements (e.g.
toys and tunnels) in an environmentally controlled room (20–
228C, 60% relative humidity, 12h light–12h dark cycle). Insti-
tutional and national guidelines for the care and use of animals
were followed and all experimental procedures involving animals
were approved by the Animal Care and Use Committee, USDA
Western Regional Research Center, Albany, CA, USA.
Diets
Semisynthetic American Institute of Nutrition (AIN)-93M(23)-
based diets were produced using either shelled whole walnut
halves (English walnuts (Juglans regia), California Walnut Com-
mission) ground to 3 mm size (WW) or tocopherol-stripped
soyabean oil (HF) as fat sources (Table 1). The WW diets incor-
porated 155 g of WW/kg diet, the equivalent of 80 g (approxi-
mately 3 ounces) of walnuts/d in humans, to give 20·5 % of
energy from fat, while the HF diet used 100 g of tocopherol-
stripped soyabean oil/kg diet supplying 20·7 % of energy
from fat. A third diet, the low-fat (LF) diet, used a lower
amount of stripped soyabean oil to supply 8·7 % of energy
from fat. The two HF provided a closely matched fatty acid
profile and the HF and WW diets were equivalent in terms
of fat, protein, carbohydrate, fibre, minerals, vitamins as well
as a- and g-tocopherol levels (7·5 and 62 mg/kg of diet, a-
and g-tocopherol, respectively). Differing amounts of pure
D-a- and D-g-tocopherol (Acros Organics) were added
(Table 1) to the walnut and the LF diets to adjust the a- and
g-tocopherol levels. The energy content of the LF diet was
adjusted by the increased carbohydrate content. All diets
were made mineral-replete by use of the Mineral mix (AIN-
93M-MX). The relatively high Se content of walnuts increased
the Se content of the WW to 0·7 mg/kg compared to 0·2 mg/kg
in the other diets. All other nutrients were provided in all
diets at concentrations that met or exceeded the minimum
recommendations of the AIN(23).
Table 1. Diet composition (weight added/kg diet) by diet (low-fat (LF), high-fat (HF) and
whole walnut (WW))
Ingredient added LF HF WW
Fat content 40 100 100
English walnuts – – 155
Soyabean oil (no additives) 40 100 –
Saturated (% of fat) 9·9 9·9 5·7
Monounsaturated (% of fat) 14·8 14·8 14·4
Polyunsaturated, total (% of fats) 37·6 37·6 39·9
18 : 3n-3:18 : 2n-6 0·2 0·2 0·24
a-Tocopherol/g-tocopherol content 7·5 mg/62 mg
g-Tocopherol 38·4 mg – 31·5 mg
a-Tocopherol 4·8 mg – 6·5 mg
Maize starch 465·7 405·7 385·8
Casein (.85 % protein) 140 140 116
Dextrinised maize starch (90–94 % tetrasaccharides) 155 155 155
Sucrose 100 100 100
Fibre 50 50 39·6
Mineral mix (AIN-93M-MX) 35 35 35
Vitamin mix (AIN-93-VX; vitamin E free) 10 10 10
L-Cys 1·8 1·8 1·8
AIN, American Institute of Nutrition.
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The diets were fed ad libitum with feed consumption
recorded two times per week. Animals were weighed every
week and then were killed by anaesthesia overdose/
diaphragm puncture at the pre-planned time sampling inter-
vals (i.e. 9, 18 and 24 weeks). Cardiac puncture was used to
obtain blood; and plasma was isolated and stored as multiple
aliquots at 2808C until analysis. Prostate genitourinary intact
(GUI) tract, i.e. bladder, seminal vesicles, coagulating and
ampulary glands were removed and weighed. GUI weight
correlates closely with other measures of prostate tumour
growth(24) and its use reduces time delays and minimises
tissue identification ambiguities that arise during dissection
as a result of the increasingly disturbed prostate tissue archi-
tecture over time in the TRAMP mouse. The GUI were
bisected along the long axis of the urethra and then one
portion flash-frozen in liquid N2 and the other stored in 10 %
buffered formalin. Finally, whole liver was removed, flash-
frozen in liquid N2 and stored at 2808C until analysis.
Prostate pathology
For histological evaluation, prostate tissues were fixed in
10 % buffered formalin, processed and embedded in paraffin.
Tissue sections (4mm thick) were cut and stained with
haematoxylin/eosin and the histology interpreted by Cardiff
and colleagues(25).
Plasma analysis
Multiplex microbead suspension arrays (Luminex Corpor-
ation) were used to simultaneously assay several plasma
analytes. Both multiple-analyte (insulin, C-reactive protein,
adiponectin, leptin, tissue plasminogen activator inhibitor 1
(tPAI-1), resistin) and single-analyte microbead assays for
insulin-like growth factor 1 (IGF-1) and glucagon were used
according to the manufacturer’s instructions (Millipore).
Plasma lipoprotein cholesterol levels were analysed using
size-exclusion HPLC coupled to post-column cholesterol
quantification as previously described(26).
Liver metabolomic analysis
Liver tissue samples (n 5) at both the 9- and 18-week time points
were selected at random from the HF, WW and LF diet groups
and analysed using mView, a metabolomic profiling system
(Metabolon, Inc.). Compounds were identified via matching
with metabolomic library entries of purified standards.
Statistical analysis
Data collected were entered into Excel spreadsheets for each
mouse; and statistical analysis was performed using ANOVA
(JMP software v9.0 for Macintosh; SAS, Inc.) after testing for
equal variances(27) and then group mean differences were
tested, with P,0·05 considered significant.
The effects of diet on whole animal weight and prostate
weight time-course were estimated in a mixed-effect
repeated-measures growth curve model using a square-root
time scale transformation to allow for slowing of growth
rates with maturity(28). The standard HF diet was chosen as
a reference, and pre-planned comparisons were made
between the LF diet and the HF diet, and between the WW
and HF diets using SAS/STATw software or R software; and
all hypothesis tests were two-sided at P,0·05. Prostate
weight measures were naturally log-transformed and were
with an assumed common mean size at 9 weeks before use
in the mixed-effect repeated-measures growth curve model.
Metabolomics data were assessed using Welch’s two-sample
t test. Q values were computed, but no absolute cut-off was set
in order to maximise the power to detect differentially
regulated metabolites; and those ratios having a P,0·05
were considered significant.
Results
As anticipated, histological evaluation at the later sampling
times found progressive changes in GUI histology. Assessment
of the histology documented the presence of a variety of
tissue derangements (e.g. engorged seminal vesicles, diffuse
atypical prostate hyperplasia); and the numbers of animals
with prostate tumours found are presented in Table 2. Upon
statistical analysis using exact logistic regression, duration
of time on the diet but not diet composition was related
significantly with the number of mice with any tumour
(P,0·0001) as well as for the number of mice with only phyl-
loides prostate tumours. Using the same analysis for the
number of mice but restricting it to mice with only neuro-
endocrine (NE) prostate tumours, both diet composition and
time on the diet approached significance (P¼0·0744 and
P¼0·0765, respectively).
Fig. 1 presents the overall body weight data, while Fig. 2
presents the prostate weight data, i.e. GUI weights over
time. GUI weight at the 9 and 24 weeks sampling time
points did not show significant differences by diet. However,
GUI prostate weights at 18 weeks did show significant
Table 2. Prostate tumour numbers and types by histopathology by diet group (low-fat (LF), high-fat (HF) and whole walnut (WW))
Diet
LF HF WW
Week 9 18 24 9 18 24 9 18 24
Total tumours/total animals 0/9 0/8 9/10 2/11 5/9 10/15 2/9 4/12 6/8
Tumour type 0 0 3 NE, 6 PHY 2 NE 3 NE, 2 PHY 4 NE, 6 PHY 1NE, 1 PHY 4 PHY 6 PHY
NE, neuroendocrine tumour; PHY, phylloides tumour.
P. A. Davis et al.1766
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differences by diet (Fig. 2) as the LF and WW diet groups’ GUI
prostate weights were markedly and statistically significantly
lower than the HF diet group’s GUI prostate weight but did
not differ from each other. GUI weights are presented
(Fig. 2), but both GUI weight and GUI weight/body weight
gave the same results upon statistical analysis. A two-way
ANOVA analysis of GUI weight data found that duration of
time on the diet reached statistical significance (P,0·05).
The effect of diet on whole animal rate of weight gain was ana-
lysed using a mixed-effect repeated-measures growth curve
model. The analysis revealed that whole body growth rate for
the WW diet animals did not differ from that of the HF diet
animals (4·75 v. 4·81 g/square root (weeks); P¼0·84), but that
whole body growth rate of the LF diet animals was about 20%
lower (3·7 g/sqrt (weeks); P¼0·001) than that of the HF and
WW diet animals. In contrast to the lack of effect on body
weight, analysis of prostate weight gain using a mixed-effect
growth curve model found that the WW diet animal’s prostate
growth (8 (SEM 2·8)%/week) was reduced by 28% (P,0·015)
relative to that of the HF diet animals (11 (SEM 2·5)%/week).
The prostate weight gain (8 (SEM 2·8)%/week) in the LF diet ani-
mals was also reduced by 28% (P,0·015).
Plasma IGF-1 (Fig. 3) differed by diet group at 18 weeks. IGF-
1 was lower (P,0·05) in the LF and WW diet animals compared
to the HF diet animals, but the WW and LF diet animals’ IGF-1
levels did not differ from each other. Plasma resistin was
lower (P,0·05) in the 18-week WW and LF animals compared
to the HF diet animals (Table 3), but the WWand LF diet animals’
resistin levels did not differ from each other. Other plasma ana-
lytes, i.e. adiponectin, insulin, C-reactive protein and leptin
showed a trend towards altered levels with diet group (Table
3), but all insulin failed to achieve statistical significance. LF
diet insulin differed only from HF diet at 18 weeks.
While plasma total cholesterol at 18 weeks did not differ
between the HF and WW diets, at 18 weeks both WW diet
group LDL-cholesterol and LDL-cholesterol:HDL-cholesterol
ratios were significantly lower when compared to the HF
diet but not compared to the LF diet (Table 4).
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Fig. 1. Body weight for the different diet groups (low-fat ( ), high-fat ( ) and whole walnut ( )) at the different sampling times. Values are means with SEM represented
by vertical bars. a,b Mean values within the same sampling time with unlike letters were significantly different (P,0·05).
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Fig. 2. Prostate weight as genitourinary tract intact (GUI) for the different diet groups (low-fat ( ), high-fat ( ) and whole walnut ( )) at the different sampling
times. Values are means with SEM represented by vertical bars. a,b Mean values within the same sampling time with unlike letters were significantly different
(P,0·05).
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Metabolomic analysis of the TRAMP mouse livers found
twenty and twenty-six metabolites among the 266 identified
named biochemicals, showing significant (P#0·05) differ-
ences in levels between the HF and WW diet groups at 9
and 18 weeks, respectively (Table 5, see the supplementary
table for metabolites identified and diet-related differences,
supplementary material for this article can be found at
http://www.journals.cambridge.org/bjn). With respect to the
lipid-related metabolites identified and found to differ by
diet, n-3 fatty acids along with n-3 fatty acid-containing
lysolipids (i.e. linoleoyl-glycerophosphoethanolamine) were
elevated in WW liver, while arachidonate, an n-6 fatty acid
along with n-6 fatty acid-containing lysolipids were decreased
compared to HF liver. In addition, hepatic sphingosine con-
tent was over 2-fold lower in WW mice compared to that of
the HF diet group at 18 weeks and WW livers had significantly
increased 9- and 13-hydroxy-octadecadienoic acids.
Discussion
High fat intake, particularly saturated fat intake, has been
associated with CVD, other metabolic diseases and some
forms of cancer including PCa(29). Walnuts, like other nuts,
are typically consumed whole, with a majority of their
energy coming from fat. Although high in fat, walnut fats are
mainly polyunsaturated and the effects of consuming walnuts
on PCa are unclear(10) and was the focus of this study. The
results of the present study demonstrate that whole walnuts
have a beneficial effect in an animal model of PCa. The
walnut diet, irrespective of its high fat content, resulted in
notable and statistically significant decreased GUI weights
and rate of tumour weight gain. The present study results par-
allel those of Adhami and colleagues(30) who demonstrated
that green tea also reduced prostate GUI weight in TRAMP
mice, which they showed correlated closely with prostate
tumour burden and occurrence. This congruence lends sup-
port to the conclusion that the WW diet effect is a result of
walnut diet-induced decreased prostate tumour growth rate
and reduced prostate tumour size.
The TRAMP model has been much criticised as a NE-cancer
model with questionable relevance to human PCa; and more
recently, the C57BL/6 TRAMP mouse has been suggested
to actually represent a mixed model of prostate carcino-
genesis(31,32). One tumour process is the phylloides tumour
which is an androgen-driven glandular prostate atypical
hyperplasia in the dorsolateral prostate (DLP) lobes while
the other is NE-cancer in the ventral prostate (VP) lobes.
This is of importance, as the TRAMP DLP lesion progression
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Fig. 3. Plasma insulin-like growth factor 1 (IGF-1) levels are presented for the different diet groups (low-fat ( ), high-fat ( ) and whole walnut ( )) at 9 weeks, and
18 weeks of ad libitum feeding. Values are means with SEM represented by vertical bars. a,b Mean values within the same sampling time with unlike letters were
significantly different (P,0·05).
Table 3. Mouse plasma analyte levels (nM) either at 9 and 18 weeks or at 18 weeks-only time points by diet group
(low-fat (LF), high-fat (HF) and whole walnut (WW))
(Number of animals, mean values with SEM)
LF diet HF diet WW diet
Analyte Weeks n Mean SEM n Mean SEM n Mean SEM
Resistin 9 5 0·19 0·03 4 0·21 0·03 8 0·21 0·02
Insulin 9 4 65·6 36·7 2 75·2 23·8 6 40·6 5·9
Resistin 18 9 0·21a 0·02 8 0·13b 0·02 11 0·16b 0·02
Insulin 18 8 60·2a 10·4 8 23·8b 5·5 10 36·6a,b 6·2
Adiponectin 18 9 0·029 0·003 8 0·048 0·010 12 0·036 0·002
CRP 18 9 93·0 5·3 8 89·8 7·1 12 84·8 3·2
Leptin 18 9 1·85 1·27 8 0·29 0·07 11 0·89 0·21
CRP, C-reactive protein.
a,b Mean values within a row with unlike superscript letters were significantly different (P,0·05).
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is more characteristic of human prostate epithelial adenocarci-
nogenesis and the majority of human PCa are adenocarcino-
mas. Conversely, NE-like carcinomas lack androgen receptor,
express synaptophysin and belong to a distinct lineage(31,32).
While the present study did not find a statistically significant
diet effect in terms of tumour occurrence, the tumour type
showed some degree of diet dependence, as NE tumours in
the walnut-fed group were nearly absent. That the walnut
diet group TRAMP mice prostates are relatively free of NE-
cancer while also showing reduced size may therefore reflect
the walnut-related effects on phylloide tumours, as these DLP
lesions account for most of TRAMP prostate weight gains(32) in
combination with possible effects on prostate NE tumours.
Given the nature of the genetic construct driving the TRAMP
tumour model, tumour suppression by walnuts was unlikely
to occur, which makes the finding of slowed growth of
importance. The specificity of the walnut diet’s effects with
respect to tumour lineages and prostate lobes affected
awaits future study.
This study’s results further suggest that PCa growth does not
appear to be a function of the level of dietary fat, as both the
WW and HF diets had the same fat level. Freedland and co-
workers have recently reported that tumour growth was not
associated with dietary fat content, using a mouse PCa xenograft
model(12,33). A similar conclusion regarding the relationship of
fat content to cancer growth has been reported recently for pan-
creatic cancer(34). The present study’s WW diet not only had the
same fat content as the HF diet, but were substantially similar in
their fatty acid profiles removing that as a factor for the diet-
associated effects noted. In addition, the absence of similar
effects despite the identical levels of a- and g-tocopherol sup-
plied by both the WW and the HF diets eliminates these toco-
pherols as a factor in the differences.
The walnut diet differs in Se (approximately 0·9 mg/kg diet
in WW v. approximately 0·2 mg Se/kg diet in the HF and
LF diets), as English walnuts are relatively high in Se (United
States Department of Agriculture National Nutrient Database
for Standard Reference, Release 24). However, the modest
levels of Se for any of the study diets tested makes it difficult
to ascribe the differences to Se, as much higher Se levels
(3·0 mg Se/kg diet) were used in studies of Se-related effects
in the TRAMP prostate model along with other rodent
models(35,36). Added difficulty in linking Se levels to effects
arises from the recent report that Se-related effects in mice
depend upon composition of the basal diet consumed along
with the differences linked to the form of Se tested(35,36).
Finally, the reduced tumour growth in the WW diet cannot
be explained by differences in energy bioavailability between
the diets, as there were no differences in body weights and
body-weight gains between WW when compared to the HF
diet-fed mice.
Diet and increased PCa have been linked via increased
IGF-1(37). The present study found that IGF-1 in WW diet
mice at 18 weeks was reduced and this was associated with
smaller tumour size and slower tumour growth rate. The
study findings of reduced IGF-1 and smaller tumour size/
growth are in agreement with other PCa studies that have
either specifically modulated or monitored IGF-1 in TRAMP
mice(30,31,38). Elevated IGF-1, along with elevated insulin,
has been reported to increase the risk of PCa via increased
cell proliferation and cell survival(39). The influence of IGF-1
levels on prostate tumour growth is highlighted by the con-
trast between both animal survival and prostate tumour cell
Table 4. Mouse plasma cholesterol levels (mM) in lipoprotein fractions and as total at 18-week time point by
diet group (low-fat (LF), high-fat (HF) and whole walnut (WW))
(Mean values with their standard errors)
Total VLDL LDL HDL LDL:HDL
Diet Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
LF 2·04 0·30 0·05 0·005 0·28b 0·05 1·72 0·26 0·16b 0·03
HF 2·70 0·46 0·05 0·005 0·66a 0·12 1·98 0·34 0·32a 0·03
WW 2·44 0·13 0·06 0·005 0·36b 0·05 2·01 0·09 0·18b 0·02
a,b Mean values within a row with unlike letters were significantly different (P,0·05).
Table 5. Liver metabolomic results
9 weeks 18 weeks
Biochemical
Campesterol 0·29* 0·40
Sphingosine 0·56 0·44*
Sphinganine 0·58* 0·45
Myristate (14:0) 0·93 0·67*
1-Myristoylglycerophosphocholine 0·49* 1·02
1-Oleoylglycerophosphocholine 0·38* 0·78
1-Palmitoleoylglycerophosphocholine 0·38* 0·78
1-Palmitoylglycerophosphoethanolamine 0·60* 1·09
1-Palmitoylglycerophosphoinositol 0·65 0·70*
2-Oleoylglycerophosphocholine 0·41* 0·47
2-Palmitoleoylglycerophosphocholine 0·42* 0·60
2-Palmitoylglycerophosphoethanolamine 0·41* 0·84
2-Hydroxystearate 1·12 1·96*
a- or g-Linolenate (18 : 3n-3 or 6) 1·61 2·17*
n-6 Fatty acid-related
Arachidonate (20:4n-6) 0·73* 0·80*
2-Arachidonoylglycerophosphocholine 0·41* 0·61
Linoleate (18 : 2n-6) 1·11 1·43*
1-Linoleoylglycerophosphoethanolamine 1·49 2·50*
2-Linoleoylglycerophosphoethanolamine 1·22 2·08*
13-HODE þ 9-HODE 1·89 1·82*
n-3 Fatty acid-related
Docosapentaenoate (n-3 DPA; 22 : 5n-3) 1·47 1·43*
2-Docosahexaenoylglycerophosphocholine 0·58* 0·74
2-Docosahexaenoylglycero
phosphoethanolamine
0·54* 0·79
EPA (20 : 5n-3) 1·23 1·89*
HODE, hydroxy-octadecadienoic acid.
*Statistically significant lipid related metabolite changes (P,0·05) are presented
as the ratio of the whole walnut diet or the high fat diet abundance at 9 and
18 weeks.
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growth in studies that altered IGF-1 levels. Studies with
increased survival and decreased tumour cell growth were
those treatments that lowered IGF-1 compared to those
where IGF-1 was unaffected(12,33,40,41). Finally, Chen et al.(42)
have reported that enterolactone, a major metabolite of
plant-based lignans inhibits PCa cell growth in vitro and does
so, at least in part via inhibition of IGF-1/IGF-1R signalling.
Recent clinical studies targeting the IGF-1R receptor alone
or in combination with chemotherapy have shown potent
PCa growth inhibition(43). However, the theoretical constructs
linking prostate tumour growth and IGF-1 signalling axis have
proven difficult to rationalise as the effects of genetically mod-
ifying IGF-1 levels or IGF-1 signalling pathways on PCa in
TRAMP mice have given mixed results(44–46). The accelerated
lesion progression and more aggressive phenotype upon
knockout of prostate epithelial cell IGF-1R in the TRAMP
model has suggested that there are different thresholds for
prostate IGF-1 signalling and that complete IGF-1R knockout
cannot recapitulate diminished but intact IGF-1/IGF-1R
signalling(46). Interestingly, Wang et al.(31) suggested that Se
inhibition of PCa tumour growth might be via effects on
both IGF-1 ligand and receptor. Again, the present study’s
WW and HF diets’ identical a- and g-tocopherol, fat content
and substantially similar fatty acid profiles removes these as
factors for the IGF-1 effects noted in this study. The extent
to which changes seen in the present study are from direct
effects on the prostate IGF-1 axis, as reported in the case of
green tea(30) and silibinin(47), remains to be further explored.
Although earlier reports have suggested that altered resistin
levels are not associated with PCa(48), recent results from Kim
and colleagues have suggested that they are elevated in
PCa(49) and stimulate PCa growth(50). The present study
revealed that mice on the WW diet had reduced levels of resis-
tin compared to the HF diet group animals, a similar pattern to
that found for IGF-1 levels. Other plasma analytes showed a
trend towards altered levels with diet, but none of these
achieved statistical significance. For example, low levels of
adiponectin have been linked to PCa(51,52) and WW diet
mice at 18 weeks had tended to have increased adiponectin
levels (P¼0·051) compared to the HF diet. Aronis et al.(53)
have very recently reported that walnut consumption acutely
increases plasma adiponectin in obese patients. The connec-
tion between changes in PCa growth and the effects of altered
resistin and, potentially, adiponectin remains to be further
clarified.
Mice in the WW group exhibited significant changes in
plasma cholesterol metabolism, specifically decreased LDL-
cholesterol and altered LDL-C:HDL-C ratios relative to those
in the HF diet. Circulating cholesterol has been reported
to promote prostate tumour growth(54,55). LNCaP PCa cells
when cultured in vitro with decreased endogenous choles-
terol availability increase their LDL receptor activity, presum-
ably in order to acquire cholesterol required to support their
growth(56). Recently, using the same TRAMP mouse model, a
high-fat (60 % of energy as fat) in combination with 0·2 %
cholesterol diet (i.e. a ‘Western’ diet) was shown to elevate
plasma cholesterol, alter LDL-C:HDL-C ratios and accelerate
prostate tumour onset and progression(55). Specific lipoprotein
classes such as LDL and HDL are associated with delivery or
removal of cell cholesterol(57) and have been linked to
PCa(58). The changes noted with diet in the plasma markers
studied are echoed in the liver metabolomics results. Interest-
ingly, despite the similarities in fats between the two diets, the
WW diet group liver metabolome showed elevations of n-3
fatty acid-related lipids while n-6 fatty acid-related lipids
decreased compared to the HF diet group livers. These
changes are probably of significance as n-3 fatty acid metab-
olism and their effects in PCa have been of high interest(3–7).
In addition, the diet-driven changes noted in the metabolites
in the liver are noteworthy, given the liver’s central role in
both IGF-1 and in plasma lipid and lipoprotein metabolism(59).
However, the linkage of PCa and other cancers with specific
fatty acids is proving to be very complex. The n-3 fatty acid,
DHA, has been recently reported as positively associated
with high-grade PCa, contrary to what the study authors had
hypothesised(60). In addition, Hardman and colleagues(14)
have just reported that while consumption of walnuts signifi-
cantly reduced the incidence, multiplicity and size of mam-
mary tumours, a cancer that shares multiple characteristics
with PCa(61), the n-3 content alone did not account for the
extent of tumour suppression due to the walnut diet.
In summary, the present study found that whole walnuts fed
as part of a HF diet (i.e. the WW diet) reduce TRAMP mouse
PCa tumour growth and size. The walnut diet-consuming
animals also showed declines in plasma IGF-1, resistin as
well as LDL, elevations of which have all been linked to
tumour growth. The study results further suggest that the
walnut effects are not due to their specific fatty acid or toco-
pherol content. The differences found between the effects of
the whole walnut and the control HF diet when coupled
with the disappointing a-tocopherol chemopreventative clini-
cal trials emphasises that whole foods and complete diets
probably exert effects beyond those of an individual constitu-
ent(6,22,62). Moreover, the disparate diet effects observed at the
same elevated dietary fat intake suggest that total dietary fat
intake is not strongly linked to PCa tumour biology.
The study results show that excluding walnuts based on
their fat content is unjustified and that consumption of wal-
nuts, already linked to reduced CVD risk(29), will probably
reduce the risk of PCa in humans. Finally, these findings
point to the need for studies using whole foods such as
walnuts to truly assess their effects on PCa and to identify
effective, food-based chemoprevention diets for PCa as well
as other cancers.
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